Table 2.

Overview of lifestyle and pharmacologic interventions in individuals with IGT^a or IFG^b

Intervention	Study	Patient Characteristics	N	Duration Main Study and Follow-up (years)	Risk Reduction Main Study and Follow-up (%)
Lifestyle
	Da Qing20	IGT	577	6	31 - 46
				20	43
	Finnish DPSc 22,28	IGT	522	3.2	58
				7	43
	DPP/DPPOS23,34	IGT and/or IFG	3324	2.8	58
				10	34
Pharmacologic
Metformin	DPP/DPPOS23,34	IGT and/or IFG	3234	2.8	31
				10	18
Acarbose	STOP-NIDDM31	IGT	14	3.3	25

^aIGT, impaired glucose tolerance

^bIFG, impaired fasting glucose

^cDPS, Diabetes Prevention Study

^dDPP, Diabetes Prevention Program

^eDPPOS, Diabetes Prevention Program Outcomes Study

^fSTOP-NIDDM, The Study to Prevent Non-insulin Dependent Diabetes Mellitus